genocea biosciences

Genocea's GEN-003 in Prime Position to Lead GH Vaccine Space
www.dddmag.com

Genocea Biosciences' investigational genital herpes (GH) vaccine, GEN-003, is better positioned to compete in the future GH treatment space, despite being slightly behind Agenus' HerpV in clinical development, according to GlobalData. Although both …

3
Like
Save
Piper Jaffray Starts Genocea Biosciences (GNCA) at Overweight
www.streetinsider.com

GEN-003 is a therapeutic vaccine for genital herpes targeting HSV-2 with top-line data from a 310-patient Phase II trial in late 2Q:15. GEN-004 is a prophylactic vaccine for pneumococcus with data from a 90-patient Phase II "challenge" study in 4Q:15.

4
Like
Save
Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2014 Results – Earnings …
seekingalpha.com

Let me first discuss GEN-003, our first in class immunotherapy candidate for the treatment of patients with genital herpes, an incurable sexually transmitted disease. For the approximately 10 million Americans diagnosed with genital herpes infections …

5
Like
Save
Biotech Stocks Touched New Lows: Synta Pharmaceuticals (NASDAQ:SNTA …
www.propertymentorgroup.com

On 7 January Genocea Biosciences, Inc. (NASDAQ:GNCA) reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the …

7
Like
Save
Market Wrap Up: Best Buy Co., Inc. (NYSE:BBY), Peabody Energy Corp. (NYSE …
www.propertymentorgroup.com

On 7 January Genocea Biosciences, Inc. (NASDAQ:GNCA) reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the …

10
Like
Save
Genocea Biosciences (GNCA) Completes GEN-003 Phase 2 Enrollment
www.streetinsider.com

Genocea Biosciences (NASDAQ: GNCA) reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the immediate post …

7
Like
Save
Genocea completes enrollment in Phase 2 genital herpes trial
vaccinenewsdaily.com

t-cell Researchers from Genocea Biosciences, Inc. recently finished enrollment for a Phase 2 clinical trial study of dose optimization for GEN-003, a treatment for genital herpes. The Phase 2 study involves more than 300 patients from 17 facilities …

7
Like
Save
Fast Moving Stocks : Brocade Communications (NASDAQ:BRCD), China BAK …
www.crazyjoys.com

Dr. Seth Hetherington, MD, chief medical officer of Genocea Biosciences, Inc. (NASDAQ:GNCA) announced that their new vaccine candidate against the genital herpes virus is entering phase 2 clinical trials. Chip Clark, president and chief executive …

10
Like
Save
Genital Herpes Vaccine is in Development; CBCD Congratulates Genocea …
www.prunderground.com

Currently there are no vaccines approved to protect against the genital herpes virus (HSV-2). However, Genocea Biosciences, a biotech company, recognized this need and has been working on such a vaccine. Dr. Seth Hetherington, MD, chief medical officer …

3
Like
Save
Genocea Biosciences (GNCA) Chip Clark on Q2 2014 Results – Earnings Call …
seekingalpha.com

The primary endpoint for this study has changed from baseline and viral shedding rate, and it will also evaluate the impact on the percentage of days with genital herpes lesions, as reported by patients. We expect to announce initial results from this …

5
Like
Save